
    
      In diabetes Type II the xerostomia is a quite frequent symptom. The trial was conducted at a
      single center. Designed and implementing UNI EN ISO 14155:2012, STROBE statement Version 4
      and was in conformity with the guidelines of the Declaration of Helsinki.

      The type of study was a randomized, cross over clinical trial to compare two treatments
      (artificial saliva spray (aldiamed(R) mouth spray) AS vs. (Tonimer(R) Throat Spray) TT .

      Twenty one subjects that were part of the epidemiological screening for asymptomatic vascular
      diseases conducted in the Irwin Lab3 of Spoltore (PE / Italy) The degree of xerostomia for
      the admission had to be at least > 2 according to a semi-quantal scale (ranging from 0 to 6)
      and patients already under treatment for xerostomia or with xerostomia score < 2, suffering
      from obesity, cancer, drug addiction or alcoholism were excluded.

      The patients had to follow a three day treatment with each product. Whereas after the first
      treatment period the two groups had to follow a wash out period of three days before the
      second treatment period could begin.

      The study consisted of a preliminary selection during screening, the measurement of
      xerostomia and random allocation, first treatment period, wash out period and finally the
      second treatment period.
    
  